Main Industry
Health Care
Main Product/Service
100% Pure Autologous Serum Eye Drops. Specially formulated for corneal epithelial defects, these customized eye drops are rich in growth factors. Made with 100% pure serum, they closely mimic the composition of natural tears and contain a wide range of nutrients. Packaged in single-use vials for easy storage. Because the ingredients are derived from the patient's own body, there is no risk of allergic reactions or rejection. Compared to traditional dry eye treatments, this solution offers greater efficacy and safety, while demonstrating excellent tolerability for corneal epithelial defects.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2018
Unified Business No.
50753068
Status
Active
Number of Employees
0
Total Paid-in
Capital
80,000,000 (NT$)
Location of Company
Taiwan
, Taoyuan City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Trend Young Vision Care INC. is a professional medical service company under the Visco Vision Group. Collaborating with ophthalmic medical institutions, the company adheres to rigorous processes and quality management, allowing medical teams to focus more on treating and caring for patients with eye conditions.
Currently, the service provided is single-dose, 100% pure autologous serum eye drops. This serum is extracted and centrifuged from the patient's own blood, with no added moisturizers, thickeners, or preservatives, making it a purely natural serum product. Because serum contains rich nutrients and growth factors, every step from preparation to cold chain services is strictly controlled to ensure no risk of contamination during the manufacturing process, thereby safeguarding product quality and safety.
Trend Young Vision Care INC. has further considered the convenience for patients in using and freezing autologous serum eye drops. Its packaging is superior to existing serum products on the market, adopting a patented single-dose design that makes it a more ideal choice for individuals with severe dry eye and corneal damage. This brings peace of mind and reassurance to both partner medical institutions and the patients who use the product.
The parent company, Visco Vision Inc. (stock code: 6782), was established in 1998. Guided by the vision of "recreating the truth, goodness, and beauty of the visual world" and driven by the mission of caring for eye health, the company focuses on the research and development of various solutions. Leveraging its independent design and manufacturing capabilities to provide comfortable and highly oxygen-permeable silicone hydrogel contact lens products, it is currently the largest manufacturer of silicone hydrogel contact lenses in Asia.
(The content above was translated by AI.)
Currently, the service provided is single-dose, 100% pure autologous serum eye drops. This serum is extracted and centrifuged from the patient's own blood, with no added moisturizers, thickeners, or preservatives, making it a purely natural serum product. Because serum contains rich nutrients and growth factors, every step from preparation to cold chain services is strictly controlled to ensure no risk of contamination during the manufacturing process, thereby safeguarding product quality and safety.
Trend Young Vision Care INC. has further considered the convenience for patients in using and freezing autologous serum eye drops. Its packaging is superior to existing serum products on the market, adopting a patented single-dose design that makes it a more ideal choice for individuals with severe dry eye and corneal damage. This brings peace of mind and reassurance to both partner medical institutions and the patients who use the product.
The parent company, Visco Vision Inc. (stock code: 6782), was established in 1998. Guided by the vision of "recreating the truth, goodness, and beauty of the visual world" and driven by the mission of caring for eye health, the company focuses on the research and development of various solutions. Leveraging its independent design and manufacturing capabilities to provide comfortable and highly oxygen-permeable silicone hydrogel contact lens products, it is currently the largest manufacturer of silicone hydrogel contact lenses in Asia.
(The content above was translated by AI.)
